Clinical AI Governance: A Framework for Healthcare Leaders

How healthcare leaders can build clinical AI governance that satisfies regulators and preserves human accountability for patient outcomes.

MRC MRC Insights

6 July 2026 · 4 min read

Clinical AI governance is the structured discipline of ensuring that AI-enabled clinical tools are deployed safely, lawfully, and accountably — with named human overseers, documented monitoring, and clear liability. For healthcare leaders, it is no longer optional: regulators on both sides of the Atlantic now impose binding obligations on those who deploy clinical AI, not merely those who build it.

Accountability begins with the principle that humans remain responsible

The foundational premise of clinical AI governance is that AI does not absorb clinical accountability. A governance framework that implicitly transfers responsibility to a vendor or an algorithm is not a framework at all. This principle should anchor every board-level discussion.

The regulatory landscape is now tri-national and converging

Healthcare leaders face a maturing, internationally aligned regulatory environment. In October 2021, the FDA, Health Canada, and the UK’s MHRA jointly published 10 guiding principles for Good Machine Learning Practice (GMLP) — the first tri-national regulatory consensus standard for AI/ML-enabled medical devices — covering rigorous software engineering, representative datasets, human-AI team performance, and post-deployment monitoring across the total product lifecycle. This consensus signals that the core expectations for clinical AI are not jurisdiction-specific quirks but durable, shared standards.

In the United States, the FDA regulates AI-enabled medical devices under a risk-based classification system — Class I (low), Class II (moderate), and Class III (high) — applying this framework to Software as a Medical Device (SaMD) and requiring Premarket Approval (PMA) or 510(k) clearance depending on risk level. Recognising that clinical AI is iterative by nature, on 4 December 2024 the FDA published final guidance on Predetermined Change Control Plans (PCCPs), enabling manufacturers to obtain pre-authorisation for specified algorithm updates within the original marketing submission — without a new submission for each modification.

The EU AI Act creates dual obligations — and cannot be contracted away

For organisations operating in or serving the European market, the EU AI Act (Regulation EU 2024/1689) is decisive. AI-enabled medical devices classified as MDR Class IIa, IIb, or III — which require Notified Body conformity assessment — are automatically classified as high-risk AI systems under Article 6(1) and Annex I, triggering a dual compliance framework in which existing MDR/IVDR obligations are supplemented by AI-specific requirements including data governance, transparency, human oversight, risk management, and post-market monitoring.

Critically, the Act reaches beyond manufacturers. Under Article 26, healthcare organisations that deploy third-party high-risk AI systems bear independent legal obligations as ‘deployers’ — including assigning named human overseers with documented competence, training, and authority; monitoring system operation continuously; ensuring input data is relevant and representative; maintaining operational logs for a minimum of six months; and reporting serious incidents — obligations that cannot be disclaimed by contract with the AI provider. Leaders who assume that procuring a certified product discharges their duty are mistaken.

Human oversight is enforceable, not aspirational

Article 14 requires that high-risk AI systems be designed so they can be effectively overseen by natural persons during use, with the ability for overseers to understand the system’s limitations, detect anomalies, remain aware of automation bias, correctly interpret outputs, and decide in any situation not to use the system. Governance frameworks must therefore build in the practical conditions for meaningful override — not merely a theoretical veto.

Post-deployment monitoring is a shared regulatory expectation

A robust governance framework treats deployment as the beginning, not the end, of oversight. The FDA, Health Canada, and MHRA jointly identified five guiding principles for PCCPs, drawing on GMLP Principle 10 — which requires that deployed models be monitored for performance and that retraining risks be managed — establishing that post-deployment monitoring is a shared international regulatory expectation, not merely a best practice. Continuous monitoring, drift detection, and incident reporting should be embedded in operational routines and assigned to accountable owners.

The UK framework is taking shape

UK-based leaders should plan for near-term regulatory clarity. The MHRA regulates AI-enabled software as a medical device when it meets the definition of a medical device or IVD, assessing it across the full product lifecycle including intended medical purpose, device classification, and post-market surveillance; the UK government’s Life Sciences Sector Plan confirmed that the MHRA will publish a dedicated regulatory framework specifically for AI as a medical device in 2026. Governance structures designed now should be flexible enough to accommodate that forthcoming detail.

Takeaway

Clinical AI governance is ultimately about preserving accountable human judgement while meeting a converging set of international obligations. The prudent course for healthcare leaders is to treat deployer duties, human oversight, and continuous monitoring as core institutional responsibilities — grounded in the enduring principle that the institution, not the algorithm, answers for the patient.

Sources

Want to talk this through for your organisation?

Get in touch